Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $213.5 million.

  • Maxcyte's Liabilities and Shareholders Equity fell 1413.29% to $213.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $902.7 million, marking a year-over-year decrease of 1204.85%. This contributed to the annual value of $239.5 million for FY2024, which is 1073.68% down from last year.
  • Maxcyte's Liabilities and Shareholders Equity amounted to $213.5 million in Q3 2025, which was down 1413.29% from $219.8 million recorded in Q2 2025.
  • Maxcyte's 5-year Liabilities and Shareholders Equity high stood at $291.0 million for Q1 2022, and its period low was $93.1 million during Q2 2021.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $267.5 million (2023), whereas its average is $253.2 million.
  • As far as peak fluctuations go, Maxcyte's Liabilities and Shareholders Equity soared by 44870.5% in 2021, and later crashed by 1413.29% in 2025.
  • Maxcyte's Liabilities and Shareholders Equity (Quarter) stood at $284.1 million in 2021, then rose by 0.89% to $286.7 million in 2022, then dropped by 6.41% to $268.3 million in 2023, then dropped by 10.74% to $239.5 million in 2024, then dropped by 10.85% to $213.5 million in 2025.
  • Its Liabilities and Shareholders Equity was $213.5 million in Q3 2025, compared to $219.8 million in Q2 2025 and $230.0 million in Q1 2025.